ASAQ Winthrop®

Sanofi

Legend
Product category

  • 3-day cure, artemisinin-based combination therapy (artesunate-amodiaquine)
Therapeutic indication

  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg
Dosing

  • Once-daily for 3 days
Efficacy

  • 28 day PCR-corrected ACPR* 94.4%–98.9%
Key features
  • Lower price compared to other prequalified artemisinin-based combination therapies (public-sector tenders)
  • Three-year shelf life
Challenges

  • Amodiaquine resistance in some countries

  • Being withdrawn from countries where SPAQ is deployed for seasonal malaria chemoprevention (SMC) following WHO recommendation
Status

  • 537 million treatments distributed since 2007

  • Approved in 33 countries
Previously
  • DNDi and partners completed development and registration
  • Incorporated into MMV portfolio via collaboration supporting phase IV safety study in Côte d’Ivoire in 2010
MMV Project Director

  • Adam Aspinall (ad interim)

* ACPR = adequate clinical and parasitological response